Diabetes and CVD

About the programme

The epidemic of diabetes will continue its growing trend in the upcoming years and in every part of the world. People with diabetes face an increased risk of cardiovascular diseases. New therapeutic solutions exist and healthcare professionals have an important role to play for their patients.

The Diabetes and CVD Educational Programme is a collaborative project that aims to raise awareness and education on diabetes and cardiovascular risk, addressing new therapeutic strategies in the field. The programme will include an awareness component, scientific resources and educational activities. 

Key Facts

• The International Diabetes Federation (IDF) estimates that the number of persons suffering from diabetes worldwide will increase by 54% to reach 642 million by 2025
• People with diabetes have an increased risk of cardiovascular disease (CVD) which is the leading cause of death in people with type 2 diabetes
• Diabetes and prediabetes are common among patients with coronary artery disease and are associated with an  impaired prognosis
• People with acute myocardial infarction and diabetes have an almost twice as high one-year mortality than those without diabetes
• People with type 2 diabetes mellitus (T2DM) often have a multifactorial risk pattern and a multifactorial treatment approach is important 

A full programme to support you in this mission

Test your knowledge

• Online poll &  quizzes
• Survey

Get and share the latest science

• European Journal of Preventive Cardiology supplement (2019)
• Literature review
• Congress sessions

Adapt your day to day knowledge and practice

• How to articles (2019)
• 5 webinars (2018 – 2019)
• 2 masterclasses & online courses (2019)
• 2 days hands-on course (2019)

Topics covered

• Global statistics on diabetes
• Diabetes prevention
• Diabetes and CV Risk (identification of risk, risk stratification, co-morbidities)
• New therapeutic strategies, glucose and risk factor control
• Metabolic syndrome, lifestyle background and modification
• Behavioural changes / Lifestyle management,  and patient empowerment
• Organisation of care and patient engagement
• Insulin resistance and pre-diabetes
• Link between diabetes and atherosclerosis
• Innovation in diabetes care and risk management
• The transition from diabetes to HFpEF
• New drug classes in diabetes

Communities involved in the project

Experts from the following groups are involved in all stages of the programme development:

• European Association of Preventive Cardiology (EAPC)
• European Association for the Study of Diabetes (EASD) Study Group on Diabetes & CVD
• ESC Council for Cardiology Practice (CCP)
• Association of Cardiovascular Nursing and Allied Professions (ACNAP)
• ESC Working Group on Aorta and Peripheral Vascular Disease
• ESC Working Group on Myocardial & Pericardial Diseases
• ESC Working Group on Thrombosis

This Programme is supported by the Boehringer Ingelheim and Lilly Diabetes Alliance and Novo Nordisk A/S  in the form of educational grants. The programme has not been influenced in any way by its sponsors.